MONTREAL, May 20, 2025 (GLOBE NEWSWIRE) -- Gildan Activewear Inc. (GIL: TSX and NYSE) (“Gildan” or “the Company”) is pleased to announce the publication of its 21st Environmental, Social, and Governance (ESG) Report, outlining the Company’s continued progress against the ten targets of its Next Generation ESG strategy. “Over the years, ESG, which is one of three pillars of our Gildan Sustainable Growth (GSG) strategy, has been foundational to support our low-cost manufacturing operations, unlocking innovat ...

NASHVILLE, Tenn., May 20, 2025 (GLOBE NEWSWIRE) -- Ryman Hospitality Properties, Inc. (NYSE: RHP) (the “Company”) announced today that its subsidiaries, RHP Hotel Properties, LP (the “Operating Partnership”) and RHP Finance Corporation (together with the Operating Partnership, the “Issuers”), intend to offer, in a private placement, subject to market and other conditions, up to $600 million aggregate principal amount of senior notes due 2033 (the “Notes”). The Notes will be senior unsecured obligations of t ...

NEW YORK, May 20, 2025 (GLOBE NEWSWIRE) -- Nexxen International Ltd. (NASDAQ: NEXN) (“Nexxen” or the “Company”), a global, flexible advertising technology platform with deep expertise in data and advanced TV, today issued a reminder to investors and analysts about its upcoming Investor Day taking place in New York City on Thursday, May 22, 2025. The event is scheduled to begin at 9:00 AM ET and conclude at approximately 12:30 PM ET. The Investor Day will feature a comprehensive overview of Nexxen’s strategi ...

Repeated positive recommendation from Data Safety Monitoring Board (“DSMB”) of pivotal Phase 3 study for lead clinical candidate Bria-IMT™ in combination with checkpoint inhibitorBria-IMT has received Fast Track designation from FDA and patient enrollment has been accelerating in the pivotal Phase 3 study in metastatic breast cancerSuccessful completion of the pivotal study may lead to a Biologics License Application submission, Priority Review, Full Approval, and commercializationInterim analysis planned a ...

– Rapid, deep, and durable reductions in high-sensitivity C-reactive protein (hs-CRP) through Day 90 achieved across all pacibekitug arms with high statistical significance as compared to placebo (p<0.0001 for all arms) – – Pacibekitug becomes the first and only IL-6 inhibitor known to demonstrate deep hs-CRP reductions with quarterly dosing in a clinical trial, achieving >85% hs-CRP reductions from baseline in the 50 mg quarterly arm – – Overall incidence rates of adverse events and serious adverse events ...

Acquired business offers the StatSeal® and WoundSeal® products, which provide hemostasis solutions that complement the wide range of procedures Merit’s portfolio supports.Acquisition projected to add approximately $18 million of revenue, on an annualized basis beginning in fiscal year 2026, with a mid-teens growth and accretive non-GAAP margin and profitability profileMerit reaffirms full-year 2025 financial guidance previously issued on April 24, 2025, and updates full-year 2025 financial guidance to inclu ...

TUS+VEN+AZA triplet achieves complete remissions (CRs) and minimal residual disease (MRD)-negativity with favorable safety in newly diagnosed AML patientsCompleted 40 mg and 80 mg TUS dose cohorts; no prolonged myelosuppression or dose-limiting toxicitiesNo dose reductions required to the standard-of-care therapy with 40 mg and 80 mg TUS dose cohortsCSRC endorsed escalation to 120 mg TUS dosingFirst patient dosed with 120 mg TUS triplet and enrollment continues SAN DIEGO and TORONTO, May 20, 2025 (GLOBE NE ...

Win supports organic growth of Denver Metro transportation and water resources portfolioRESTON, Va., May 20, 2025 (GLOBE NEWSWIRE) -- Bowman Consulting Group Ltd. (NASDAQ: BWMN), a national engineering services and program management firm, has been awarded a $1.3 million contract from the Aerotropolis Area Coordination Metropolitan District (the “District”) for the design and development of ATEC Parkway, a two-mile roadway in The Aurora Highlands, located in Aurora, Colorado. Under the contract, Bowman is d ...

Core Insights - Acoramidis has shown significant clinical benefits in reducing the incidence of atrial fibrillation (AF) and cardiovascular-related hospitalizations in patients with transthyretin amyloid cardiomyopathy (ATTR-CM) [1][4][5] - The drug has received regulatory approvals in multiple regions, including the U.S. and Europe, indicating its potential as a treatment option for ATTR-CM [1][6] Group 1: Clinical Outcomes - In a post-hoc analysis of the ATTRibute-CM study, acoramidis reduced the annual frequency of cardiovascular hospitalizations (CVH) due to AF/atrial flutter (AFL) by 43% compared to placebo [1][4] - The incidence of new-onset AF/AFL was reduced by 17% in patients with no prior history of AF when treated with acoramidis [1][4] - A 42% reduction in composite all-cause mortality (ACM) and recurrent CVH events was observed at Month 30 relative to placebo [3] - Acoramidis treatment led to a greater than 50% reduction in ACM and CVH in participants with variant ATTR-CM compared to placebo [7] Group 2: Functional Capacity and Quality of Life - Patients with variant ATTR-CM treated with acoramidis showed a clinically significant slower decline in functional capacity and quality of life compared to placebo [7] - At Month 30, the mean difference in the 6-minute walk distance was 86.7 meters in favor of acoramidis (p = 0.0048) [7] - The KCCQ-OS score change from baseline at Month 30 was 20.3 points higher in the acoramidis group compared to placebo (p = 0.0019) [7] Group 3: Regulatory Approvals and Future Directions - Acoramidis is approved as Attruby™ by the U.S. FDA and as BEYONTTRA by the European Commission and other regulatory agencies [1][6] - The company plans to present more data on the benefits of acoramidis for ATTR-CM patients at future medical meetings [6]

MONTREAL, May 20, 2025 (GLOBE NEWSWIRE) -- Midland Exploration Inc. (“Midland”) (TSX-V: MD) is pleased to announce the start of an exploration program for gold on its Caniapisc Au project, and also present results from the 2024 till survey, in the Eeyou Istchee James Bay and Canispiscau regions. The Caniapisc Au project is wholly owned by Midland and consists of 94 claims covering an area of 47 square kilometres. Highlights: Initiation of the June exploration program, including prospecting and a soil sampli ...